Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: Analysis of the southwest oncology group database for antimicrotubule-platinum therapy

Karen Kelly, Kari Chansky, Philip Mack, Primo N Lara, Fred R. Hirsch, Wilbur A. Franklin, Antoinette J. Wozniak, Martin J. Edelman, Stephen K. Williamson, David R Gandara

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Objective Histologic subtyping has been advocated to select chemotherapy for patients with advanced-stage non-small-cell lung cancer (NSCLC). To determine whether histologic subtype was associated with efficacy for the commonly used antimicrotubule (AMT) agents, paclitaxel, docetaxel, and vinorelbine plus a platinum compound, we examined the Southwest Oncology Group (SWOG) lung cancer database. Methods Data from 4 randomized trials (S9308, S9509, S9806, and S0003) administering an AMT agent plus platinum in patients receiving first-line treatment for advanced-stage NSCLC were analyzed. Overall survival (OS) and progression-free survival (PFS) comparisons were performed using Cox proportional hazard regression, adjusting for sex. Median survival times were estimated by Kaplan-Meier. Results Of 1146 patients included in this analysis, 640 had adenocarcinoma (56%), 220 had squamous cell carcinoma (19%), 121 had large cell carcinoma (11%), and 165 had NSCLC not otherwise specified (NOS) (14%). Median OS times by histologic subtypes were 8.5, 8.4, 8.2, and 9.6 months, respectively, and median PFS times were 4.2, 4.3, 4.3, and 4.6 months, respectively. No difference in OS or PFS was observed by histologic subtype and, specifically, between nonsquamous and squamous histologies. Conclusions This pooled analysis from 4 SWOG trials using an AMT-platinum regimen did not show a difference in survival outcomes by histologic subtype. Because the majority of patients with advanced NSCLC continue to receive chemotherapy, defining molecular-based predictive markers of responsiveness is warranted.

Original languageEnglish (US)
Pages (from-to)627-635
Number of pages9
JournalClinical Lung Cancer
Volume14
Issue number6
DOIs
StatePublished - Nov 2013

Keywords

  • Chemotherapy outcomes
  • Histology
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: Analysis of the southwest oncology group database for antimicrotubule-platinum therapy'. Together they form a unique fingerprint.

  • Cite this